Generic selection criteria for safety and patient benefit [XII] : Comparing the physicochemical and pharmaceutical properties of brand-name and generic tulobuterol tape

被引:0
|
作者
Shimokawa, Ken-ichi [1 ]
Yotsukura, Kayo [1 ]
Nozawa, Mitsuru [2 ]
Wada, Yuko [3 ]
Ishii, Fumiyoshi [3 ]
机构
[1] Meiji Pharmaceut Univ, Dept Pharmaceut Sci, 2-522-1 Noshio, Kiyose, Tokyo 2048588, Japan
[2] Triad Japan Co Ltd, Sagamihara, Kanagawa, Japan
[3] Meiji Pharmaceut Univ, Dept Selfmedicat & Hlth Care Sci, Tokyo, Japan
关键词
Transdermal therapeutic drug; brand-name drug; generic drug; tulobuterol tape; USABILITY;
D O I
10.5582/ddt.2023.01076
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Physicochemical properties (drug release, peel strength, adhesion, and stiffness) of Hokunalin((R)) Tape (Hokunalin) and 13 generic transdermal bronchodilator patches containing tulobuterol were characterized and evaluated for comparison. Drug-release studies evaluating sustained release behavior demonstrated better performance by the drug Hokunalin, than the generics MED, YP, Sawai, and Teikoku. Hokunalin yield a 16.2% release 1 hour after initiation, 30.1% at 3 hours, 50.0% at 8 hours. In comparison, the generics MED, YP, Sawai, and Teikoku showed an intermediate release behavior to that of Hokunalin, with more than 80% release after 8 hours. A 90-degree peel adhesion test for tape peel strength demonstrated that the generic MED (4.99 N), YP (3.26 N), Sawai (4.17 N), and Teikoku (4.37 N) tapes yielded significantly higher values compared to Hokunalin (2.66 N). Probe tack tests, evaluating adhesive strength, yielded significantly higher values for the generics HMT (4.89 N) and Towa (4.25 N) compared to Hokunalin (3.66 N). Furthermore, for the stiffness-softness test, a significantly higher value was obtained for each generic yielded compared to Hokunalin (3.7-degree). These factors are important components of product qualities that affect treatment efficacy, including "ease of application" and other usability factors.
引用
下载
收藏
页数:6
相关论文
共 45 条
  • [21] DOUBLE-BLIND RANDOMIZED STUDY COMPARING BRAND-NAME AND GENERIC PHENYTOIN MONOTHERAPY
    MIKATI, M
    BASSETT, N
    SCHACHTER, S
    EPILEPSIA, 1992, 33 (02) : 359 - 365
  • [22] Safety Evaluation of Generic and Brand-Name Products of Ampicillin Sodium/Sulbactam Sodium for Injection
    Yabumoto, Chizuru
    Tsugane, Mamiko
    Nozawa, Takako
    Nomura, Kaori
    Takashi, Sozu
    Uejima, Etsuko
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 249 - 249
  • [23] Comparison of the Pharmaceutical Characteristics of Brand-name and Generic Pramipexole Extended-release Tablets and Their PTP Usability
    Akiyama, Shigeo
    Maida, Chieko
    Miyamoto, Etsuko
    Doi, Nobuyuki
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2019, 139 (09): : 1185 - 1193
  • [24] Safety of Brand-Name to Generic Angiotensin II Receptor Blockers Substitution: Uncertainty Persists.
    Leclerc, Jacinthe
    Blais, Claudia
    Rochette, Louis
    Hamel, Denis
    Guenette, Line
    Beaudoin, Claudia
    Poirier, Paul
    CIRCULATION, 2018, 138
  • [25] No Significant Outcome Benefit for Brand-Name Versus Generic Tacrolimus in Kidney Transplant Recipients: SRTR Analysis
    Goldfarb, D.
    Poggio, E.
    Flechner, S.
    Fatica, R.
    Schold, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [26] ECONOMIC AND PATIENT OUTCOMES OF GENERIC AND BRAND-NAME STATINS USED IN ROUTINE CLINICAL PRACTICE IN SPAIN
    Sicras-Mainar, A.
    Rejas, J.
    Sanchez-Alvarez, L.
    Navarro-Artieda, R.
    Darba, J.
    VALUE IN HEALTH, 2018, 21 : S451 - S451
  • [27] Evaluating Real-World Effectiveness and Safety of Generic and Brand-Name Imatinib in Chronic Myeloid Leukemia
    Muir, Michele
    Johnson, Jasmine
    Shu, Sitong
    Chen, Hui-Han
    Ozawa, Sachiko
    Muluneh, Benyam
    BLOOD, 2021, 138
  • [28] Generic and brand-name drugs. Are different criteria sufficiently taken into account before granting market authorisation?
    Laroche, ML
    Merle, L
    ACTA CLINICA BELGICA, 2006, 61 : 48 - 50
  • [29] Healthy User Bias in Comparative Safety Studies for Brand-Name vs. Generic Products: The Example of Warfarin
    Bird, Steven T.
    Flowers, Natasha
    Zhao, Yueqin
    McKean, Stephen
    Izem, Rima
    Wernecke, Michael
    Kozlowski, Steven
    MaCurdy, Thomas E.
    Kelman, Jeffrey A.
    Graham, David J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (05) : 1037 - 1045
  • [30] A Patient with Corneal Epithelial Disorder That Developed after Administration of a Latanoprost Generic, but Not a Brand-Name Drug, Eye Drop
    Takada, Yukihisa
    Okada, Yuka
    Fujita, Norihito
    Saika, Shizuya
    CASE REPORTS IN OPHTHALMOLOGICAL MEDICINE, 2012, 2012